<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01919190</url>
  </required_header>
  <id_info>
    <org_study_id>MSE402</org_study_id>
    <nct_id>NCT01919190</nct_id>
  </id_info>
  <brief_title>EXPAREL Administered by Infiltration Into the TAP for Prolonged Postsurgical Analgesia in Lower Abdominal Surgeries</brief_title>
  <acronym>TRANSCEND</acronym>
  <official_title>Assessing the Impact of EXPAREL(R) on Opioid Use and Patient Reported Outcomes When Administered by Infiltration Into the Transversus Abdominis Plane (TAP) Under Ultrasound Guidance for Prolonged Postsurgical Analgesia in Lower Abdominal Surgeries</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pacira Pharmaceuticals, Inc</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pacira Pharmaceuticals, Inc</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this prospective, blinded assessor, randomized trial is to assess opioid use&#xD;
      and patient-reported outcomes of EXPAREL as a foundation in postsurgical pain therapy in&#xD;
      Transversus Abdominis Plane (TAP) infiltration in lower abdominal surgical procedures.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The purpose of this prospective, blinded assessor, randomized trial is to assess opioid use&#xD;
      and patient-reported outcomes of EXPAREL as a foundation in postsurgical pain therapy in&#xD;
      Transversus Abdominis Plane (TAP) infiltration in lower abdominal surgical procedures;&#xD;
      primary endpoint signal seen during pre-specified interim analysis.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Due to reasons unrelated to safety; primary endpoint signal seen during pre-specified interim&#xD;
    analysis.&#xD;
  </why_stopped>
  <start_date>August 2013</start_date>
  <completion_date type="Actual">February 2014</completion_date>
  <primary_completion_date type="Actual">December 2013</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Total Opioid Consumption Post Surgery (Cumulative Total) Until Discharge Readiness or Post Surgery Day 4</measure>
    <time_frame>From surgery through 4 days postsurgery</time_frame>
    <description>Total Opioid Consumption Post Surgery (cumulative total) Until Discharge Readiness or Post Surgery Day 4</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Overall Benefit of Analgesic Score (OBAS) at Day 3</measure>
    <time_frame>Postsurgical day 1 through day 3</time_frame>
    <description>Severity of postsurgical pain, satisfaction with pain management, and impact of opioid-related symptom distress measured using the Overall Benefit of Analgesic Score (OBAS) - primary endpoint is mean difference in OBAS at Day 3. (0=minimal pain and 4=maximum imaginable pain)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Extent and Degree of Anesthetic Blockade</measure>
    <time_frame>Prior to TAP, immediately postoperatively, and daily through discharge or Day 4</time_frame>
    <description>Extent and degree of anesthetic blockage measured using a 5-point sensation scale.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Severity of Postsurgical Pain</measure>
    <time_frame>Immediately in PACU postsurgery and prior to pain medication until discharge (or Day 4)</time_frame>
    <description>Severity of postsurgical pain measured using an 11-point numerical rating scale (NRS 0-10).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Recovery</measure>
    <time_frame>Daily through Post Op Day 4</time_frame>
    <description>Measured using the Quality of Recovery 15 questionnaire (QoR-15)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency of Patient Calls Post-discharge</measure>
    <time_frame>Post-discharge through 4 days postsurgery</time_frame>
    <description>Frequency of patient calls post-discharge related to pain and unscheduled hospital/surgeon visits</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">67</enrollment>
  <condition>Pain</condition>
  <arm_group>
    <arm_group_label>EXPAREL</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>EXPAREL (266mg/20 ml) with 40 mL of 0.9% normal saline for a total volume of 60 mL, 30 mL to be administered to the right TAP and 30 mL to be administered to the left TAP</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>The placebo control will be established using a grade-2 sham, no infiltration will occur</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>EXPAREL</intervention_name>
    <description>TAP with EXPAREL</description>
    <arm_group_label>EXPAREL</arm_group_label>
    <other_name>bupivacaine liposome injectable suspension.</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Placebo using grade-2 sham, no infiltration</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Males and females &gt;18 years of age&#xD;
&#xD;
          -  American Society of Anesthesiologists (ASA) physical status 1-3&#xD;
&#xD;
          -  Undergoing either lower abdominal surgery defined as Laparoscopic Hysterectomy&#xD;
             (female), Laparoscopic Myomectomy (female), Laparoscopic Colectomy (male/female)&#xD;
&#xD;
          -  Physically and mentally able to give full informed consent to participate in this&#xD;
             study and complete all study assessments within the timeframes required (including&#xD;
             electronic diaries should patient be discharged prior to day 4)&#xD;
&#xD;
          -  Capable of returning the diary after POD 4 by mail (preferably) or upon follow up&#xD;
             visit.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  History of hypersensitivity or idiosyncratic reactions to amide-type local&#xD;
             anesthetics.&#xD;
&#xD;
          -  Any patient whose anatomy, or surgical procedure, in the opinion of the Investigator,&#xD;
             might preclude the potential successful local administration of EXPAREL.&#xD;
&#xD;
          -  Patients who have received any investigational drug within 30 days prior to EXPAREL&#xD;
             administration, or planned administration of another investigational product or&#xD;
             procedure during their participation in this study.&#xD;
&#xD;
          -  Any chronic condition requiring use of opioids for treatment of a medical condition&#xD;
             for 2 weeks or more prior to surgery.&#xD;
&#xD;
          -  Confirmed pregnancy at time of enrollment or breast feeding (females of child-bearing&#xD;
             potential).&#xD;
&#xD;
          -  Patients that would constitute a contraindication to participation in the study, or&#xD;
             cause inability to comply with the study requirements.&#xD;
&#xD;
          -  Any patient with diagnosed or potential metastatic disease.&#xD;
&#xD;
          -  Any condition that in the investigator's opinion might be harmed or be a poor&#xD;
             candidate for participation in the study (such as patients requiring long acting&#xD;
             opioids as part of the induction medications).&#xD;
&#xD;
          -  Initiation of treatment with any of the following medications within 1 month of study&#xD;
             drug administration or if the medication(s) are being given to control pain: selective&#xD;
             serotonin reuptake inhibitors (SSRIs), selective norepinephrine reuptake inhibitors&#xD;
             (SNRIs), gabapentin, pregabalin (Lyrica®), or duloxetine (Cymbalta®)&#xD;
&#xD;
          -  History of suspected or known addiction to, or abuse of, illicit drug(s), prescription&#xD;
             medicine(s), or alcohol within the past 2 years.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kay Warnott, RN</last_name>
    <role>Study Director</role>
    <affiliation>Pacira Pharmaceuticals, Inc</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Florida Hospital</name>
      <address>
        <city>Winter Park</city>
        <state>Florida</state>
        <zip>32792</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Memorial Health University Medical Center</name>
      <address>
        <city>Savannah</city>
        <state>Georgia</state>
        <zip>31404</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Northwestern University</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60208</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Louisville</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Berkshire Medical Center</name>
      <address>
        <city>Pittsfield</city>
        <state>Massachusetts</state>
        <zip>01210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Minnesota</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55404</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Montefiore Medical Center</name>
      <address>
        <city>Bronx</city>
        <state>New York</state>
        <zip>10467</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Duke University</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27705</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fairview Hospital</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44111</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Ohio State University</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Thomas Jefferson University</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19107</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UPMC St. Margaret's Hospital</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. John Hospital</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77081</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>August 6, 2013</study_first_submitted>
  <study_first_submitted_qc>August 6, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 8, 2013</study_first_posted>
  <results_first_submitted>December 11, 2014</results_first_submitted>
  <results_first_submitted_qc>June 11, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">July 2, 2021</results_first_posted>
  <last_update_submitted>June 11, 2021</last_update_submitted>
  <last_update_submitted_qc>June 11, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 2, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bupivacaine</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>EXPAREL</title>
          <description>EXPAREL (266 mg/20 mL) with 40 mL of 0.9% normal saline for a total volume of 60 mL, 30 mL to be administered to the right TAP and 30 mL to be administered to the left TAP.&#xD;
EXPAREL</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>The placebo control was established using a grade-2 sham; no infiltration occurred.&#xD;
Placebo</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="33">Met eligibility criteria</participants>
                <participants group_id="P2" count="34">Met eligibility criteria</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="30"/>
                <participants group_id="P2" count="34"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Intra-op findings, etc.</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Who met eligibility criteria</population>
      <group_list>
        <group group_id="B1">
          <title>EXPAREL</title>
          <description>EXPAREL (266 mg/20 mL) with 40 mL of 0.9% normal saline for a total volume of 60 mL, 30 mL to be administered to the right TAP and 30 mL to be administered to the left TAP.&#xD;
EXPAREL</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>The placebo control was established using a grade-2 sham; no infiltration occurred.&#xD;
Placebo</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="33"/>
            <count group_id="B2" value="34"/>
            <count group_id="B3" value="67"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Under 75</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="32"/>
                    <measurement group_id="B2" value="33"/>
                    <measurement group_id="B3" value="65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Over 75</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="27"/>
                    <measurement group_id="B2" value="28"/>
                    <measurement group_id="B3" value="55"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="33"/>
                    <measurement group_id="B2" value="34"/>
                    <measurement group_id="B3" value="67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Total Opioid Consumption Post Surgery (Cumulative Total) Until Discharge Readiness or Post Surgery Day 4</title>
        <description>Total Opioid Consumption Post Surgery (cumulative total) Until Discharge Readiness or Post Surgery Day 4</description>
        <time_frame>From surgery through 4 days postsurgery</time_frame>
        <group_list>
          <group group_id="O1">
            <title>EXPAREL</title>
            <description>EXPAREL (266 mg/20 mL) with 40 mL of 0.9% normal saline for a total volume of 60 mL, 30 mL to be administered to the right TAP and 30 mL to be administered to the left TAP&#xD;
EXPAREL</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>The placebo control will be established using a grade-2 sham, no infiltration will occur&#xD;
Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Total Opioid Consumption Post Surgery (Cumulative Total) Until Discharge Readiness or Post Surgery Day 4</title>
          <description>Total Opioid Consumption Post Surgery (cumulative total) Until Discharge Readiness or Post Surgery Day 4</description>
          <units>Opioid consumption (mg)</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="33"/>
                <count group_id="O2" value="34"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.79" spread="NA">All efforts have been made to obtain the raw data but it cannot be located and a Measure of Dispersion cannot be calculated. The analysis was performed years ago, all data available have been entered.</measurement>
                    <measurement group_id="O2" value="3.72" spread="NA">All efforts have been made to obtain the raw data but it cannot be located and a Measure of Dispersion cannot be calculated. The analysis was performed years ago, all data available have been entered.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other (legacy)</non_inferiority_type>
            <p_value>&gt;0.8</p_value>
            <method>ANCOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Overall Benefit of Analgesic Score (OBAS) at Day 3</title>
        <description>Severity of postsurgical pain, satisfaction with pain management, and impact of opioid-related symptom distress measured using the Overall Benefit of Analgesic Score (OBAS) - primary endpoint is mean difference in OBAS at Day 3. (0=minimal pain and 4=maximum imaginable pain)</description>
        <time_frame>Postsurgical day 1 through day 3</time_frame>
        <group_list>
          <group group_id="O1">
            <title>EXPAREL</title>
            <description>EXPAREL (266 mg/20 mL) with 40 mL of 0.9% normal saline for a total volume of 60 mL, 30 mL to be administered to the right TAP and 30 mL to be administered to the left TAP&#xD;
EXPAREL</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>The placebo control will be established using a grade-2 sham, no infiltration will occur&#xD;
Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Benefit of Analgesic Score (OBAS) at Day 3</title>
          <description>Severity of postsurgical pain, satisfaction with pain management, and impact of opioid-related symptom distress measured using the Overall Benefit of Analgesic Score (OBAS) - primary endpoint is mean difference in OBAS at Day 3. (0=minimal pain and 4=maximum imaginable pain)</description>
          <units>units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="33"/>
                <count group_id="O2" value="34"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.05" spread="0.56"/>
                    <measurement group_id="O2" value="4.63" spread="0.56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other (legacy)</non_inferiority_type>
            <p_value>0.0456</p_value>
            <method>Mixed Models Analysis</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Extent and Degree of Anesthetic Blockade</title>
        <description>Extent and degree of anesthetic blockage measured using a 5-point sensation scale.</description>
        <time_frame>Prior to TAP, immediately postoperatively, and daily through discharge or Day 4</time_frame>
        <population>The analysis was not conducted due to the early termination of this study.</population>
        <group_list>
          <group group_id="O1">
            <title>EXPAREL</title>
            <description>EXPAREL (266mg /20 mL) with 40 mL of 0.9% normal saline for a total volume of 60 mL, 30 mL to be administered to the right TAP and 30 mL to be administered to the left TAP&#xD;
EXPAREL</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>The placebo control will be established using a grade-2 sham, no infiltration will occur&#xD;
Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Extent and Degree of Anesthetic Blockade</title>
          <description>Extent and degree of anesthetic blockage measured using a 5-point sensation scale.</description>
          <population>The analysis was not conducted due to the early termination of this study.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Severity of Postsurgical Pain</title>
        <description>Severity of postsurgical pain measured using an 11-point numerical rating scale (NRS 0-10).</description>
        <time_frame>Immediately in PACU postsurgery and prior to pain medication until discharge (or Day 4)</time_frame>
        <population>The analysis was not conducted due to the early termination of this study.</population>
        <group_list>
          <group group_id="O1">
            <title>EXPAREL</title>
            <description>EXPAREL (266 mg/20 mL) with 40 mL of 0.9% normal saline for a total volume of 60 mL, 30 mL to be administered to the right TAP and 30 mL to be administered to the left TAP&#xD;
EXPAREL</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>The placebo control will be established using a grade-2 sham, no infiltration will occur&#xD;
Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Severity of Postsurgical Pain</title>
          <description>Severity of postsurgical pain measured using an 11-point numerical rating scale (NRS 0-10).</description>
          <population>The analysis was not conducted due to the early termination of this study.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Quality of Recovery</title>
        <description>Measured using the Quality of Recovery 15 questionnaire (QoR-15)</description>
        <time_frame>Daily through Post Op Day 4</time_frame>
        <population>The analysis was not conducted due to the early termination of this study.</population>
        <group_list>
          <group group_id="O1">
            <title>EXPAREL</title>
            <description>EXPAREL (266 mg/20 mL) with 40 mL of 0.9% normal saline for a total volume of 60 mL, 30 mL to be administered to the right TAP and 30 mL to be administered to the left TAP&#xD;
EXPAREL</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>The placebo control will be established using a grade-2 sham, no infiltration will occur&#xD;
Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Quality of Recovery</title>
          <description>Measured using the Quality of Recovery 15 questionnaire (QoR-15)</description>
          <population>The analysis was not conducted due to the early termination of this study.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Frequency of Patient Calls Post-discharge</title>
        <description>Frequency of patient calls post-discharge related to pain and unscheduled hospital/surgeon visits</description>
        <time_frame>Post-discharge through 4 days postsurgery</time_frame>
        <population>The analysis was not conducted due to the early termination of this study.</population>
        <group_list>
          <group group_id="O1">
            <title>EXPAREL</title>
            <description>EXPAREL (266 mg/20 mL) with 40 mL of 0.9% normal saline for a total volume of 60 mL, 30 mL to be administered to the right TAP and 30 mL to be administered to the left TAP&#xD;
EXPAREL</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>The placebo control will be established using a grade-2 sham, no infiltration will occur&#xD;
Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Frequency of Patient Calls Post-discharge</title>
          <description>Frequency of patient calls post-discharge related to pain and unscheduled hospital/surgeon visits</description>
          <population>The analysis was not conducted due to the early termination of this study.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>10 days</time_frame>
      <group_list>
        <group group_id="E1">
          <title>EXPAREL</title>
          <description>EXPAREL (266 mg/20 mL) with 40 mL of 0.9% normal saline for a total volume of 60 mL, 30 mL to be administered to the right TAP and 30 mL to be administered to the left TAP&#xD;
EXPAREL</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>The placebo control will be established using a grade-2 sham, no infiltration will occur&#xD;
Placebo</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="34"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Postoperative anemia exacerbation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="34"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Postoperative abdominal hemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="34"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Subtherapeutic international normalized ration (INR)</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="34"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="34"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Paci</name_or_title>
      <organization>Pacira Pharmaceuticals, Inc.</organization>
      <phone>1-855-793-9727</phone>
      <email>MedInfo@pacira.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

